Skip to content
★ Sign in to follow
邦創

邦睿生技-創 Stock: price and insider trades · Taiwan

TW·Mcap NT$2.8BHealth Care

邦睿生技-創: what insiders have been doing

We have very little insider data for 邦睿生技-創 so far: the most recent filing dates from 19 July 2023. With so few records, no pattern can be drawn yet. Source: insider filings from TWSE / TPEx (MOPS). Past trades are no guide to future returns.

Insider Decl.
6
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 6,412 of 26,897 companies
64.8
score / 100
Value
41
Quality
89
FCF yld2.3%
Earn yld3.6%
EV/EBITDA24.1x
ROE17%
Gross mgn78%
Net mgn33%
Debt/EBITDA0.2x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

NT$92
Analyst consensus
·
Income statement
RevenueNT$306.3M
Gross profitNT$238.5M78% margin
EBITDANT$118.4M39% margin
Net incomeNT$102.5M32.5% margin
Valuation
PER (trailing)26.3x
P/Book4.3x
Beta0.13
Balance sheet & cash
Market capNT$2.8B
Total debtNT$22M
Free Cash FlowNT$65.8M
Debt / Equity1%
Profitability & ownership
ROE17.4%
ROA9.7%
Last declaration on 19 July 2023
Declarations6 total
  • ●
    Related company / holdingExecutives
    €22kest.0MOPS
    15,000 sharesShareTWSETWMOPS:6955:112/07/19:博邦有限公司:01y8fgr
  • ●
    ManagerExecutives
    €15kest.0MOPS
    10,000 sharesShareTWSETWMOPS:6955:112/07/19:楊婉嫈:0wzhbhq
  • ●
    ManagerExecutives
    €15kest.0MOPS
    10,000 sharesShareTWSETWMOPS:6955:112/07/19:莊明山:1c4e0kf
  • ●
    DirectorExecutives
    €22kest.0MOPS
    15,000 sharesShareTWSETWMOPS:6955:112/07/19:徐振騰:0pk6z0n
  • ●
    ManagerExecutives
    €15kest.0MOPS
    10,000 sharesShareTWSETWMOPS:6955:112/07/19:楊佩62278:1r1rkw9
  • ●
    ManagerExecutives
    €15kest.0MOPS
    10,000 sharesShareTWSETWMOPS:6955:112/07/19:廖英智:12pk87f

6 of 6 declarations

About 邦睿生技-創

Bangrui Biotechnology-Creation is a company listed on the XTAI market, specializing in the biotechnology sector.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations